iRadimed/$IRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRadimed
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Ticker
$IRMD
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
160
ISIN
US46266A1097
Website
iRadimed Metrics
BasicAdvanced
$730M
37.07
$1.55
0.92
$0.64
1.18%
Price and volume
Market cap
$730M
Beta
0.92
52-week high
$63.29
52-week low
$42.34
Average daily volume
60K
Dividend rate
$0.64
Financial strength
Current ratio
8.867
Quick ratio
5.94
Total debt to equity
0.066
Dividend payout ratio (TTM)
39.74%
Profitability
EBITDA (TTM)
23.434
Gross margin (TTM)
76.91%
Net profit margin (TTM)
26.33%
Operating margin (TTM)
30.13%
Effective tax rate (TTM)
20.79%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
14.92%
Return on equity (TTM)
23.81%
Valuation
Price to earnings (TTM)
37.07
Price to revenue (TTM)
9.695
Price to book
8.11
Price to tangible book (TTM)
8.42
Price to free cash flow (TTM)
52.884
Free cash flow yield (TTM)
1.89%
Free cash flow per share (TTM)
108.63%
Dividend yield (TTM)
1.11%
Forward dividend yield
1.18%
Growth
Revenue change (TTM)
11.04%
Earnings per share change (TTM)
10.72%
3-year revenue growth (CAGR)
18.73%
10-year revenue growth (CAGR)
14.81%
3-year earnings per share growth (CAGR)
23.17%
10-year earnings per share growth (CAGR)
19.17%
What the Analysts think about iRadimed
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
Bulls say / Bears say
IRADIMED CORPORATION reported record revenue of $19.4 million for Q4 2024, marking its fourteenth consecutive quarter of revenue growth, driven by sustained demand for its IV infusion pumps. (iradimed.com)
The company increased its regular quarterly cash dividend to $0.17 per share from $0.15, reflecting confidence in its financial position and commitment to returning value to shareholders. (iradimed.com)
IRADIMED's new facility in Orlando, Florida, is on track for completion by mid-2025, providing additional space to support future growth and operational efficiency. (iradimed.com)
The company's gross profit margin slightly declined to 76.1% in Q4 2024 from 76.9% in the same period of 2023, indicating potential pressure on profitability. (iradimed.com)
IRADIMED's reliance on domestic sales, which accounted for 85% of total revenue in Q4 2024, may expose the company to risks associated with market saturation and limited international diversification. (iradimed.com)
The construction of the new facility requires significant capital expenditure, with approximately $5.5 million anticipated in 2025, which could impact short-term cash flow and financial flexibility. (iradimed.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
iRadimed Financial Performance
Revenues and expenses
iRadimed Earnings Performance
Company profitability
iRadimed News
AllArticlesVideos
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
GlobeNewsWire·2 months ago
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRadimed stock?
iRadimed (IRMD) has a market cap of $730M as of July 18, 2025.
What is the P/E ratio for iRadimed stock?
The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 37.07 as of July 18, 2025.
Does iRadimed stock pay dividends?
Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of July 18, 2025, the dividend rate is $0.64 and the yield is 1.18%. iRadimed has a payout ratio of 39.74% on a trailing twelve-month basis.
When is the next iRadimed dividend payment date?
The next iRadimed (IRMD) dividend payment date is unconfirmed.
What is the beta indicator for iRadimed?
iRadimed (IRMD) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.